Next-Generation Oncology Devices & Solutions Market by Component, Cancer Type, End User

Description

List of Tables

[186 Pages Report] The Next-Generation Oncology Devices & Solutions Market size was estimated at USD 15.62 billion in 2023 and expected to reach USD 18.97 billion in 2024, at a CAGR 21.15% to reach USD 59.84 billion by 2030.

Global Next-Generation Oncology Devices & Solutions Market

KEY MARKET STATISTICS
Base Year [2023]	USD 15.62 billion
Estimated Year [2024]	USD 18.97 billion
Forecast Year [2030]	USD 59.84 billion
CAGR (%)	21.15%

Next-Generation Oncology Devices & Solutions Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Next-Generation Oncology Devices & Solutions Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Next-Generation Oncology Devices & Solutions Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Oncology Devices & Solutions Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Brainlab, Danaher Corporation, Exact Sciences Corp., F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc., Guardant Health Inc., Hologic, Inc., Illumina, Inc., Johnson & Johnson Services Inc., Merck & Co., Inc., Myriad Genetics, Inc., NanoString Technologies, Inc., Natera, Inc., NeoGenomics, Inc., Novartis AG, Paige.AI, Inc., PerkinElmer, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Royal Philips, Siemens AG, Sysmex Corporation, Takara Bio USA, Inc., Thermo Fisher Scientific Inc., and Veracyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Oncology Devices & Solutions Market to forecast the revenues and analyze trends in each of the following sub-markets:

Component
- Devices
  - Advanced Forms of Radiation Therapy
  - High-Intensity Focused Ultrasound
- Software
Cancer Type
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Lung Cancer
End User
- Diagnostic Imaging Centers
- Hospitals
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Next-Generation Oncology Devices & Solutions Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Next-Generation Oncology Devices & Solutions Market?

3. What are the technology trends and regulatory frameworks in the Next-Generation Oncology Devices & Solutions Market?

4. What is the market share of the leading vendors in the Next-Generation Oncology Devices & Solutions Market?

5. Which modes and strategic moves are suitable for entering the Next-Generation Oncology Devices & Solutions Market?

Product Code: MRR-2E76C3E47F82

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Next-Generation Oncology Devices & Solutions Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing prevalence of cancer across the globe
  - 5.1.1.2. Rising preference for minimally invasive techniques of diagnosis and treatment
  - 5.1.1.3. Government Initiatives to improve healthcare infrastructure
- 5.1.2. Restraints
  - 5.1.2.1. High initial investments for manufacturing of next generation devices
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing technological advancements oncology testing and treatment
  - 5.1.3.2. Proliferation of personalized and advanced genome medicine
- 5.1.4. Challenges
  - 5.1.4.1. Concern associated with the insufficient standardization of diagnostics
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Next-Generation Oncology Devices & Solutions Market, by Component

6.1. Introduction
6.2. Devices
- 6.3.1. Advanced Forms of Radiation Therapy
- 6.3.2. High-Intensity Focused Ultrasound
6.3. Software

7. Next-Generation Oncology Devices & Solutions Market, by Cancer Type

7.1. Introduction
7.2. Breast Cancer
7.3. Cervical Cancer
7.4. Colorectal Cancer
7.5. Lung Cancer

8. Next-Generation Oncology Devices & Solutions Market, by End User

8.1. Introduction
8.2. Diagnostic Imaging Centers
8.3. Hospitals

9. Americas Next-Generation Oncology Devices & Solutions Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Next-Generation Oncology Devices & Solutions Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Next-Generation Oncology Devices & Solutions Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Abbott Laboratories
- 13.1.2. Agilent Technologies, Inc.
- 13.1.3. Bio-Rad Laboratories, Inc.
- 13.1.4. Brainlab
- 13.1.5. Danaher Corporation
- 13.1.6. Exact Sciences Corp.
- 13.1.7. F. Hoffmann-La Roche Ltd.
- 13.1.8. GE HealthCare Technologies, Inc.
- 13.1.9. Guardant Health Inc.
- 13.1.10. Hologic, Inc.
- 13.1.11. Illumina, Inc.
- 13.1.12. Johnson & Johnson Services Inc.
- 13.1.13. Merck & Co., Inc.
- 13.1.14. Myriad Genetics, Inc.
- 13.1.15. NanoString Technologies, Inc.
- 13.1.16. Natera, Inc.
- 13.1.17. NeoGenomics, Inc.
- 13.1.18. Novartis AG
- 13.1.19. Paige.AI, Inc.
- 13.1.20. PerkinElmer, Inc.
- 13.1.21. QIAGEN N.V.
- 13.1.22. Quest Diagnostics Incorporated
- 13.1.23. Royal Philips
- 13.1.24. Siemens AG
- 13.1.25. Sysmex Corporation
- 13.1.26. Takara Bio USA, Inc.
- 13.1.27. Thermo Fisher Scientific Inc.
- 13.1.28. Veracyte, Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing